Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Launches Victoza Rival In The US

Following Past Negotiations, Teva Launches Its Victoza Authorized Generic

27 Jun 2024

• By Adam Zamecnik

Photograph of liraglutide pens — • Source: Shutterstock

Related Content

Liraglutide Generics May Need More Robust Analytical Methods After Novo Petition

10 Oct 2017

Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming

12 Jan 2024

At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023

05 Jan 2023

Biocon And Zentiva Hail Milestone Liraglutide Approval In UK

02 Apr 2024

Adalvo Secures First EU Approval For Victoza Rival

19 Jun 2024

Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries

02 Dec 2022

Weight-Loss Powerhouse Saxenda Among Dozens Of New FDA Guidance Docs

24 May 2024

What’s Next? Five Things To Look Out For In June

01 Jun 2024

Sandoz Victoza Settlement Sets Up Face-Off With Teva And Viatris

13 Apr 2022

US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone

18 Jun 2019

Novo Nordisk Has Its Best Year Ever

31 Jan 2024

Additional Topics

United States Biosimilars Generic Drugs BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.